Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on November 6 backed approval for a batch of medicines including Sanofi’s blockbuster hopeful dupilumab and Chugai Pharmaceutical’s anti-PD-L1 antibody atezolizumab. The Pharmaceutical Affairs and Food Sanitation...read more